Art. 5 Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

Procedure for designation and removal from the register

In forcesince 7 Aug 2009cited 20×
1.

In order to obtain the designation of a medicinal product as an orphan medicinal product, the sponsor shall submit an application to the Agency at any stage of the development of the medicinal product before the application for marketing authorisation is made.

2.

The application shall be accompanied by the following particulars and documents:

(a)

name or corporate name and permanent address of the sponsor;

(b)

active ingredients of the medicinal product;

(c)

proposed therapeutic indication;

(d)

justification that the criteria laid down in Article 3(1) are met and a description of the stage of development, including the indications expected.

3.

The Commission shall, in consultation with the Member States, the Agency and interested parties, draw up detailed guidelines on the required format and content of applications for designation.

4.

The Agency shall verify the validity of the application and prepare a summary report to the Committee. Where appropriate, it may request the sponsor to supplement the particulars and documents accompanying the application.

5.

The Agency shall ensure that an opinion is given by the Committee within 90 days of the receipt of a valid application.

6.

When preparing its opinion, the Committee shall use its best endeavours to reach a consensus. If such a consensus cannot be reached, the opinion shall be adopted by a majority of two-thirds of the members of the Committee. The opinion may be obtained by written procedure.

7.

Where the opinion of the Committee is that the application does not satisfy the criteria set out in Article 3(1), the Agency shall forthwith inform the sponsor. Within 90 days of receipt of the opinion, the sponsor may submit detailed grounds for appeal, which the Agency shall refer to the Committee. The Committee shall consider whether its opinion should be revised at the following meeting.

8.

The Agency shall forthwith forward the final opinion of the Committee to the Commission, which shall adopt a decision within 30 days of receipt of the opinion. Where, in exceptional circumstances, the draft decision is not in accordance with the opinion of the Committee, the decision shall be adopted in accordance with the regulatory procedure referred to in Article 10a(2). The decision shall be notified to the sponsor and communicated to the Agency and to the competent authorities of the Member States.

9.

The designated medicinal product shall be entered in the Community Register of Orphan Medicinal Products.

10.

Each year the sponsor shall submit to the Agency a report on the state of development of the designated medicinal product.

11.

To have the designation of an orphan medicinal product transferred to another sponsor, the holder of the designation shall make specific application to the Agency. In consultation with the Member States, the Agency and interested parties, the Commission shall draw up detailed guidelines on the form in which applications for transfer shall be made and the content of such applications and all the particulars of the new sponsor.

12.

A designated orphan medicinal product shall be removed from the Community Register of Orphan Medicinal Products:

(a)

at the request of the sponsor;

(b)

if it is established before the market authorisation is granted that the criteria laid down in Article 3 are no longer met in respect of the medicinal product concerned;

(c)

at the end of the period of market exclusivity as laid down in Article 8.

The 10 that are cited most themselves, of 20.

  • Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for i…2Law

    … в съответствие с основните насоки, изготвени съгласно член 5, параграф 3 на Регламент (ЕО) № 141/2000: а) документацията се придружава, в …

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. Now Pharm AG v European Commission.Decision

    Next it should be stated that a feature of the procedure introduced by Article 5 of Regulation No 141/2000 is the essential part assigned to an objective and in-depth scientific assessment by the Committee of the effect of the potential …

    9 Sep 2010 · 62008TJ0074

  • Judgment of the General Court (Sixth Chamber), 22 January 2015. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines AgencDecision

    As regards the designation of medicinal products as orphan medicinal products, Article 3 of Regulation No 141/2000 sets out the criteria for designation, while Article 5 of the regulation lays down the procedure to be followed for the …

    22 Jan 2015 · 62012TJ0140

  • Regulation (EC) No 596/2009 of the European Parliament and of the Council of 18 June 200…Lawamends

  • Judgment of the General Court (Second Chamber) of 5 December 2018. Bristol-Myers Squibb Pharma EEIG v European Commission and European MedicDecision

    … for the medicinal product for human use Empliciti (Elotuzumab) — Article 5(1)2(b) of Regulation (EC) No 141/2000 — Article 5(8) of Regulation No 141/2000 — Obligation to state reasons) In Case T‑329/16, Bristol-Myers Squibb Pharma …

    5 Dec 2018 · 62016TJ0329

  • Judgment of the General Court (Seventh Chamber) of 16 May 2019 (Extracts). GMP-Orphan (GMPO) v European Commission.Decision

    As for the second phase of the procedure, namely that of marketing authorisation for an orphan medicinal product, it starts, where relevant, after the product concerned has been designated as an orphan medicinal product. It is apparent …

    16 May 2019 · 62017TJ0733

  • Judgment of the General Court (Ninth Chamber) of 26 January 2022. Mylan IRE Healthcare Ltd v European Commission.Decision

    In the third place, a feature of the procedure introduced by Article 5 of Regulation No 141/2000 is the essential part assigned to an objective and in-depth scientific assessment by the COMP of the effect of the potential medicinal …

    26 Jan 2022 · 62016TJ0303

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision

    With regard to the possibility of benefiting from exemption measures, it is true that Article 5(1) of Regulation No 141/2000 prevents an undertaking holding a marketing authorisation for a medicinal product to treat a rare condition from …

    9 Sep 2010 · 62007TJ0264

  • Judgment of the Court (Sixth Chamber) of 3 March 2016. Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA).Decision

    Under the procedure set out in Article 5 of Regulation No 141/2000, a medicinal product designated as an orphan medicinal product by the European Commission is entered in the Community Register of Orphan Medicinal Products.

    3 Mar 2016 · 62015CJ0138

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    On 19 March 2019, the applicant requested that the COMP re-examine its opinion of 19 December 2018 in accordance with Article 5(7) of Regulation No 141/2000. To that end, it submitted new analyses comparing Trecondi-treosulfan with …

    23 Sep 2020 · 62019TJ0549